Skip to main content

Table 3 Intention to treat analysis of enrolled study subjects

From: Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial

  Completion of the study
 Baseline (n = 87) Normal echogenic response Fatty liver
Tocotrienols (n = 43) 15/43 28/43
  34.9% 65.1%
Placebo (n = 44) 8/44 36/44
  18.2% 81.8%
Tocotrienols vs Placebo P = 0.038  
  1. Drop-out subjects were computed as having an unchanged diagnosis of fatty liver from baseline.
  2. [Helmert-Pearson’s Chi Square; Numbers’09, GraphPad].